Profile data is unavailable for this security.
About the company
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).
- Revenue in USD (TTM)10.00k
- Net income in USD-37.28m
- Incorporated2003
- Employees35.00
- LocationGlycoMimetics Inc9708 Medical Center DriveROCKVILLE 20850United StatesUSA
- Phone+1 (240) 243-1201
- Fax+1 (240) 243-1018
- Websitehttps://glycomimetics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galecto Inc | 0.00 | -30.83m | 16.48m | 13.00 | -- | 0.5854 | -- | -- | -1.15 | -1.15 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -63.50 | -48.46 | -78.33 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -14.82m | 16.57m | 2.00 | -- | 0.5323 | -- | -- | -1.64 | -1.64 | 0.00 | 5.74 | 0.00 | -- | -- | 0.00 | -1.53 | -13.35 | -1.62 | -13.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1.81 | -- | -- | -- |
| Talis Biomedical Corp | 989.00k | -57.21m | 16.76m | 99.00 | -- | 0.2958 | -- | 16.95 | -31.44 | -31.44 | 0.5434 | 31.11 | 0.0092 | -- | 14.87 | 9,989.90 | -53.08 | -68.18 | -58.71 | -74.22 | 97.27 | -- | -5,784.73 | -1,615.96 | -- | -- | 0.00 | -- | -55.65 | -2.24 | 45.13 | -- | -1.83 | -- |
| Nascent Biotech Inc | 0.00 | -2.09m | 16.80m | -- | -- | 550.02 | -- | -- | -0.0147 | -0.0147 | 0.00 | 0.0002 | 0.00 | -- | -- | -- | -346.80 | -815.53 | -- | -- | -- | -- | -- | -548.75 | -- | -- | 0.8045 | -- | -100.00 | -- | -495.46 | -- | -- | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 17.16m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| Kintara Therapeutics Inc | 0.00 | -9.51m | 17.17m | 2.00 | -- | -- | -- | -- | -4.08 | -4.08 | 0.00 | 0.1071 | 0.00 | -- | -- | 0.00 | -131.55 | -220.94 | -185.60 | -329.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 40.24 | -- | 78.93 | -- |
| Alaunos Therapeutics Inc | 6.00k | -26.77m | 17.45m | 1.00 | -- | 3.64 | -- | 2,908.94 | -1.67 | -1.67 | 0.0004 | 0.2996 | 0.0002 | -- | 12.00 | 6,000.00 | -97.94 | -74.83 | -147.22 | -89.57 | -- | -- | -446,233.30 | -10,508.06 | -- | -19.25 | 0.00 | -- | -99.83 | -49.08 | 6.86 | -- | -15.56 | -- |
| GlycoMimetics Inc | 10.00k | -37.28m | 17.47m | 35.00 | -- | 0.6041 | -- | 1,746.99 | -0.5791 | -0.5791 | 0.0002 | 0.4486 | 0.0002 | -- | 0.0581 | 285.71 | -72.29 | -43.60 | -81.84 | -47.82 | -- | -- | -372,767.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Talphera Inc | 651.00k | -14.31m | 17.50m | 15.00 | -- | 1.07 | -- | 26.89 | -0.8945 | -0.8863 | 0.0368 | 0.9612 | 0.0237 | -- | -- | 43,400.00 | -51.96 | -22.60 | -67.70 | -28.55 | -- | -- | -2,197.39 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
| Aytu Biopharma Inc | 93.76m | -13.68m | 17.54m | 150.00 | -- | 0.5699 | -- | 0.1871 | -2.65 | -2.65 | 18.21 | 5.53 | 0.6792 | 2.42 | 2.93 | 625,053.30 | -9.91 | -33.56 | -25.58 | -52.81 | 65.32 | 56.89 | -14.60 | -73.81 | 0.6923 | 0.216 | 0.352 | -- | 11.10 | 96.56 | 84.33 | -- | -- | -- |
| VBI Vaccines Inc | 9.41m | -83.99m | 17.57m | 131.00 | -- | -- | -- | 1.87 | -6.93 | -6.93 | 0.4818 | -0.2166 | 0.0923 | 1.40 | 37.05 | 71,839.70 | -81.40 | -46.58 | -171.57 | -58.62 | -24.06 | -277.46 | -881.79 | -2,755.98 | 0.2116 | -1.60 | 1.13 | -- | 702.40 | 20.94 | 17.18 | -- | -32.07 | -- |
| Minerva Neurosciences Inc | 0.00 | -31.60m | 17.83m | 9.00 | -- | -- | -- | -- | -4.48 | -4.48 | 0.00 | -5.23 | 0.00 | -- | -- | 0.00 | -61.90 | -49.89 | -65.32 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
| Lumos Pharma Inc | 1.53m | -37.13m | 18.26m | 33.00 | -- | 1.05 | -- | 11.98 | -4.59 | -4.59 | 0.1886 | 2.15 | 0.0332 | -- | 8.01 | 46,212.12 | -80.89 | -29.78 | -90.15 | -32.32 | -- | -- | -2,434.69 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Synlogic Inc | 3.21m | -73.22m | 18.26m | 6.00 | -- | 1.36 | -- | 5.70 | -10.62 | -10.62 | 0.4576 | 1.15 | 0.0495 | -- | -- | 534,166.70 | -113.09 | -40.57 | -134.57 | -43.82 | -- | -- | -2,284.68 | -3,245.93 | -- | -- | 0.00008 | -- | 185.68 | 5.99 | 13.40 | -- | -48.05 | -- |
| Sensei Biotherapeutics Inc | 0.00 | -31.92m | 18.55m | 27.00 | -- | 0.3171 | -- | -- | -1.20 | -1.20 | 0.00 | 2.33 | 0.00 | -- | -- | 0.00 | -36.55 | -47.03 | -39.39 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0241 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
Data as of May 31 2024. Currency figures normalised to GlycoMimetics Inc's reporting currency: US Dollar USD
45.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Mar 2024 | 9.54m | 14.81% |
| Invus Public Equities Advisors LLCas of 31 Mar 2024 | 8.59m | 13.33% |
| Octagon Capital Advisors LPas of 31 Mar 2024 | 3.00m | 4.66% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.75m | 4.26% |
| AXA Investment Managers UK Ltd.as of 31 Mar 2024 | 1.59m | 2.46% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 1.11m | 1.73% |
| Millennium Management LLCas of 31 Mar 2024 | 746.95k | 1.16% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 715.89k | 1.11% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 510.91k | 0.79% |
| Geode Capital Management LLCas of 31 Mar 2024 | 505.15k | 0.78% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
